Veronica Miller, PhD, Director

300x300 miller veronica Veronica Miller, PhD, is Director of the Forum for Collaborative Research and Adjunct Professor at the University of California, Berkeley School of Public Health. With more than 30 years of experience in clinical research, drug development, and regulatory science, she leads multi-stakeholder collaborations that accelerate the development and access to innovative therapies, diagnostics, and prevention strategies. Under her leadership, the Forum advances regulatory science across infectious diseases, liver diseases, transplantation, rare diseases, and ophthalmology. Dr. Miller is a Committee on Teaching Excellence (CoTE) recognized educator and mentor, has authored more than 185 publications, and is internationally recognized for advancing collaborative approaches to biomedical innovation and public health. She received the Distinguished Advocacy Service Awards from the American Association for the Study of Liver Diseases in November 2024.

If you have questions or need additional information, please feel free to reach out to Dr. Miller’s Executive Assistant at This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Selected recent publications:

  1. Zannad F, Sanyal A, Butler J, Miller V, Harrison SA. Integrating liver endpoints in clinical trials of cardiovascular and kidney disease. Nature Medicine 2024; 10.1038/s41591-024-03223-z.
  2. Ljungman P, Chemaly RF, Khawaya F, Alain S, Avery R, Badshah C, Boeckh M, Fournier M, Hodowanec A, Komatsu T, Limaye AP, Manuel O, Natori Y, Navarro D, Pikis A, Razonable RR, Westman G, Miller V, Griffiths PD, Kotton CN for the CMF Definitions Working Group. Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from Transplant Associated Virus Infections Forum. Clin Inf Dis. 2024; 10.1093/cid/ciae321.
  3. Murdock N, Alajaji NE, Schaefer R, Boone CA, Campo RE, Dore GJ, Gandhi M, Gorospe JR, Gulick RM, Hodder SL, Liu J, Rhee MS, Rooney JF, Vannappagari V, Wilkin T, Miller V. Long-acting HIV treatments: study design, logistics, and access. Open Forum Infectious Diseases 2024; 10.1093/ofid/ofae337.
  4. Zannad F, Sanyal A, Butler J, Ferreira JP, Girerd N, Miller V, Pandey A, Parikh CR, Ratziu V, Younossi ZM, Harrison SA. MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials. Journal of Internal Medicine 2024; 10.1111/joim.13793.
  5. Peters MG, Yuen MF, Terrault N, Fry J, Lampertico P, Gane E, Hwang C, Stamm LM, Leus M, Maini MK, Mendez P, Lonjon-Domanec I, Berg T, Wang S, Mishra P, Donaldson E, Buchholz S,  Miller V, Lenz O. Chronic hepatitis B finite treatment: similar and different concerns with new drug classes. Clin Inf Dis 2023; 10.1093/cid/ciad506.
  6. Wedermeyer H, Leus M, Battersby TR, Glenn J, Gordien E, Kamili S, Kapoor J, Kessler HH, Lenz O, Luetgehetmann M, Mixson-Hayden T, Simon CO, Thomson M, Westman G, Miller V, Terrault N, Lampertico P. HDV RNA assays: performance characteristics, clinical utility, and challenges. Hepatology 2023; 10.1097/HEP.0000000000000584.
  7. Kidwell KM, Roychoudhury S, Wendelberger B, Scott J, Moroz T, Yin S, Majumder M, Zhong J, Huml RA, Miller V. Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles. Orphanet J Rare Dis. 2022; 17(1): 186.10.1186/s13023-022-02342-5.
  8. Zoulim F, Zlotnick A, Buchholz S, Donaldson E, Fry J, Gaggar A, Hu J, Kann M, Lenz O, Lin K, Mani N, Nassal M, Delaney W, Wang S, Westman G, Miller V, Janssen HLA. Nomenclature of HBV core protein-targeting antivirals. Nat Rev Gastroenterol Hepatol 2022; 19(12): 748-750.10.1038/s41575-022-00700-z.
  9. Parkin N, Gao F, Grebe E, Cutrell A, Das M, Donnell D, Duerr A, Glidden DV, Hughes JP, Murray J, Robertson MN, Zinserling J, Lau J, Miller V. Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project. Clin Pharmacol Ther. 2022; 10.1002/cpt.2830.
  10. Imlay H, Baum P, Brennan DC, Hanson KE, Hodges MR, Hodowanec AC, Komatsu TE, Ljungman P, Miller V, Natori Y, Nickeleit V, O'Rear J, Pikis A, Randhawa PS, Sawinski D, Singh H K, Westman G, Limaye AP. Consensus Definitions of BK Polyomavirus Nephropathy in Renal Transplant Recipients for Clinical Trials. Clin Inf Dis. 2022; 75(7): 1210-1216.10.1093/cid/ciac071.

For a full CV and additional publications: click here

Email:  This e-mail address is being protected from spambots. You need JavaScript enabled to view it